EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effectiveness and safety of finerenone in IgA nephropathy patients

Kuipeng Yu, Dengren Li, Xin Fan, Ke Zhao, Chunjie Wang, Fang Bai, Lei Liu, Xiangdong Yang

Nephrology Dialysis Transplantation · 29.05.2026 · 41 (6) · 1129-1137

DOI: 10.1093/ndt/gfaf240 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 11.11.2025. Verfasst von Kuipeng Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Angiotensin-Converting Enzyme Inhibitors, Naphthyridines, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Youth Foundation of Shandong Natural Science Foundation, ECCM Program of the Clinical Research Center of Shandong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis and a common cause of end-stage kidney disease. This study aimed to evaluate the effectiveness and safety of finerenone in combination with an angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker (ACEI/ARB) regimen in IgAN patients.

Methods

Our study was a single-center, observational, retrospective clinical study. Fifty-two primary IgAN patients were added. Patients were divided into two groups: the finerenone combined with ACEI/ARB group and the ACEI/ARB group. The primary endpoint was treatment response, defined as the percentage change in urinary protein/creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) from baseline to 6 months. The secondary endpoint was the safety of finerenone, with adverse events recorded during treatment. Clinical data were collected from IgAN patients.

Results

Of the 52 IgAN patients enrolled, 19 were in the finerenone combined with ACEI/ARB group and 33 in the ACEI/ARB group. At 6 months, the percentage change in UPCR was significantly greater in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group [–52.10% (interquartile range, IQR –65.71%, –6.12%) vs –21.25% (IQR –39.84%, –6.19%); P = .04]. Furthermore, the UPCR was lower in the finerenone combined with ACEI/ARB group [0.41 g/g (IQR 0.30, 0.72) vs 0.68 g/g (IQR 0.49, 1.10); P = .024]. Serum albumin levels were higher in the finerenone combined with ACEI/ARB group than in the ACEI/ARB group (44.84 ± 2.35 g/L vs 42.96 ± 3.27 g/L; P = .033). No significant changes in eGFR were observed between the groups (P = .091). The response rate was significantly higher in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group (73.7% vs 39.4%, P = .017). No serious adverse events were observed in either group.

Conclusions

In real-world settings, the finerenone combined with ACEI/ARB regimen significantly improved outcomes in IgAN patients, effectively reducing proteinuria levels and increasing serum albumin levels, while maintaining relatively stable eGFR and exhibiting safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAAngiotensin-Converting Enzyme InhibitorsNaphthyridinesAngiotensin Receptor AntagonistsHumansFemaleMaleRetrospective StudiesAdultGlomerular Filtration RateFollow-Up StudiesMiddle AgedPrognosisDrug Therapy, CombinationKidney Function TestsProteinuriaTreatment Outcome

Stichwörter der Autor:innen

ACEI/ARBIgANeffectivenessfinerenonesafety

Substanzen

Angiotensin-Converting Enzyme InhibitorsNaphthyridinesfinerenoneAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Blood Purification, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Förderung

  • Youth Foundation of Shandong Natural Science Foundation
  • ECCM Program of the Clinical Research Center of Shandong University

Zitieren

APA

Yu, K., Li, D., Fan, X., Zhao, K., Wang, C., Bai, F., Liu, L., & Yang, X. (2026). Effectiveness and safety of finerenone in IgA nephropathy patients. Nephrology Dialysis Transplantation, 41(6), 1129-1137. https://doi.org/10.1093/ndt/gfaf240

Vancouver

Yu K, Li D, Fan X, Zhao K, Wang C, Bai F, et al. Effectiveness and safety of finerenone in IgA nephropathy patients. Nephrology Dialysis Transplantation. 2026;41(6):1129-1137. doi:10.1093/ndt/gfaf240

BibTeX
@article{Yu2026,
  author = {Yu, Kuipeng and Li, Dengren and Fan, Xin and Zhao, Ke and Wang, Chunjie and Bai, Fang and Liu, Lei and Yang, Xiangdong},
  title = {Effectiveness and safety of finerenone in IgA nephropathy patients},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {6},
  pages = {1129--1137},
  doi = {10.1093/ndt/gfaf240}
}
Kostenlos starten →